Biocartis announces new data on early CAR-T vector load assessment with Idylla presented at ASTCT: A Potential Breakthrough in LBCL Treatment Monitoring
Non-regulated information
Biocartis appoints Randy Polonsky as CFO
Non-regulated information
Biocartis announces six Idylla abstracts to be presented at AMP 2024 Annual Meeting
Non-regulated information
Biocartis appoints renowned precision oncology expert, Dr. W. Michael Korn, as Chief Medical and Scientific Officer
Non-regulated information
Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing
Non-regulated information
Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region
Non-regulated information
Recapitalization Completed and Product Portfolio Expansion
Non-regulated information
Biocartis Hosts Corporate Workshop and Announces Seven Idylla Abstracts to be Presented at AMP 2023 Annual Meeting
Non-regulated information
Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio
Non-regulated information
Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit